Affiliation:
1. Cleveland Clinic, Department of Biomedical Engineering, Cleveland, OH, USA
2. Cleveland Clinic, Center for Neurological Restoration, Cleveland, OH, USA
Abstract
Over the past two decades, aerobic exercise has emerged as a mainstream recommendation to aid in treating Parkinson’s disease (PD). Despite the acknowledgement of the benefits of exercise for people with PD (PwPD), frequently, exercise recommendations lack specificity in terms of frequency, intensity and duration. Additionally, conflating physical activity with exercise has contributed to providing vague exercise recommendations to PwPD. Therefore, the beneficial effects of exercise may not be fully realized in PwPD. Data provided by animal studies and select human trials indicate aerobic exercise may facilitate structural and functional changes in the brain. Recently, several large human clinical trials have been completed and collectively support the use of aerobic exercise, specifically high-intensity aerobic exercise, in improving PD motor symptoms. Data from these and other studies provide the basis to include aerobic exercise as an integral component in treating PD. Based on positive clinical findings and trials, it is advised that PwPD perform aerobic exercise in the following dose: 3x/week, 30–40-minute main exercise set, 60–80% of heart rate reserve or 70–85% of heart rate max. In lieu of heart rate, individuals can achieve an intensity of 14–17 on a 20-point RPE scale. Ongoing clinical trials, SPARX3 and CYCLE-II, have potential to further develop patient-specific exercise recommendations through prognostic modeling.
Subject
Cellular and Molecular Neuroscience,Neurology (clinical)
Reference51 articles.
1. Parkinson’s disease Foundation, Statistics on Parkinson’s, https://www.parkinson.org/Understanding-Parkinsons/Statistics, Accessed March 30, 2020.
2. Global, regional, and national burden of neurological disorders during 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015;GBD Neurological Disorders Collaborator Group;Lancet Neurol,2017
3. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression;Parkinson Study Group;JAMA,2002
4. Does levodopa slow or hasten the rate of progression of Parkinson’s disease?;Fahn;J Neurol,2005
5. Behavioral motor recovery in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned squirrel monkey (Saimiri sciureus): Changes in striatal dopamine and expression of tyrosine hydroxylase and dopamine transporter proteins;Petzinger;J Neurosci Res,2006
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献